Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer

Table 3

Patient characteristics in the conventional and hypo-RT treatment groups.

	Level	Con-RT, n (%)	Hypo-RT, n (%)
n		57 (39.86)	86 (60.14)
Age	<65	27 (47.4)	34 (39.5)	0.450
	≥65	30 (52.6)	52 (60.5)
Gender	Female	4 (7.0)	9 (10.5)	0.685
	Male	53 (93.0)	77 (89.5)
Tumor stage	IIIA	37 (64.9)	47 (54.7)	0.295
	IIIB	20 (35.1)	39 (45.3)
PS	0	29 (50.9)	50 (58.1)	0.494
	1	28 (49.1)	36 (41.9)
Pathology	Adenocarcinoma	18 (31.6)	35 (40.7)	0.353
	Squamous cell carcinoma	39 (68.4)	51 (59.3)
Chemotherapy modality	Concurrent	22 (38.6)	36 (41.9)	0.830
	Sequential	35 (61.4)	50 (58.1)
PET-CT planning	Yes	24 (42.1)	39 (45.3)	0.702
	No	33 (57.9)	47 (54.7)
PTV (cc), median [IQR]		121.5 [69.0, 190.5]	114.0 [67.5, 178.1]	0.759

Hypo-RT: hypofractionated RT; Con-RT: conventional RT; PS: performance status; PTV: planning target volume; IQR: interquartile range.